Abstracts tagged "B cells"

Abstract Number: 9 • 2018 ACR/ARHP Annual Meeting
Integration of Cytokine Profiles with Distinct B-Cell Functions Reveals a Specific Micro-Environmental Framework in Autoimmune Diseases
Quentin Simon¹, Alexis Grasseau², Bénédicte Rouvière², Laetitia Le Pottier², Divi Cornec³, Maria Orietta Borghi⁴, Rocio Aguilar Quesada⁵, Yves Renaudineau^2,6, Marta Alarcón-Riquelme⁷, Jacques-Olivier Pers¹ and Sophie Hillion^2,6, ¹U1227, Université de Brest, Inserm, Labex IGO, CHU de Brest, Brest, France, ²U1227, Lymphocytes B et Autoimmunité, Université de Brest, Inserm, Brest, France, ³Hopital La Cavale Blanche, Brest, France, ⁴University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁵Biobanco Del Sistema Sanitario Publico de Andalucía, Sevilla, Spain, ⁶CHU de Brest, Brest, France, ⁷Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain
Background/Purpose: The functional duality of B cells is central to balance immune homeostasis by regulating or promoting the immune response. However, the mechanisms by which…
Abstract Number: 108 • 2018 ACR/ARHP Annual Meeting
Sex-Specific Expression of CXorf21 Provide Molecular Explanation for the Fundamental Difference in Male and Female Immune Response: An Explanation for Female-Bias SLE Pathogenesis
R. Hal Scofield¹, Valerie M Harris², Biji T. Kurien³ and Kristi A. Koelsch⁴, ¹Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Section of Endocrinology and Diabetes, University of Oklahoma Health Sciences Center, Okalahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is complex autoimmune disorders characterized by B cell hyperactivity resulting in autoantibody and cytokine production. Approximately 90% of patients are…
Abstract Number: 2077 • 2018 ACR/ARHP Annual Meeting
Pathological Osteogenesis and Inflammation in Experimental Spondyloarthritis Are Associated with Aberrant Type H Blood Vessels and Development of High Endothelial Venules Accompanied By Ectopic Lymphoid Structures in Bone Marrow
Merlijn Kaaij¹, Jan Piet van Hamburg², George Kollias³, Dominique Baeten¹, Leonie van Duivenvoorde¹ and Sander W. Tas², ¹Department of Clinical Immunology & Rheumatology and Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Amsterdam Rheumatology & immunology Center | Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Spondyloarthritis (SpA) is characterized by pathological osteogenesis, inflammation and extensive angiogenesis in inflamed tissues. TNF plays a central role in SpA pathology and transgenic…
Abstract Number: 10 • 2018 ACR/ARHP Annual Meeting
Fibroblast like Synoviocytes (FLS) Are Capable of Inducing Phenotypical Changes Including Class Switch Recombination (CSR) in Naive B Cells, but Additional Factors Are Required to Trigger Immunoglobulin Secretion
Dennis Bleck¹, Torsten Lowin², Matthias Schneider³ and Georg Pongratz⁴, ¹Rheumatology Policlinic & Hiller Research Unit, Medical Faculty, University Hospital, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany, ²Department and Hiller Research Center for Rheumatology, University Hospital Duesseldorf, Duesseldorf, Germany, ³Department and Hiller Research Center for Rheumatology, Heinrich-Heine University, Duesseldorf, Germany, ⁴Dpt. of Rheumatology - Hiller Research Center Rheumatology, University Hospital Duesseldorf, Duesseldorf, Germany
Background/Purpose: Rheumatoid Arthritis (RA) is a disease characterized by chronic inflammation of the synovial tissue in joints. It is driven by highly activated B cells.…
Abstract Number: 111 • 2018 ACR/ARHP Annual Meeting
BAFF Inhibition Attenuates Fibrosis in Bleomycin-Induced Scleroderma Model Via Modulating the Regulatory and Effector B-Cell Balance
Takashi Matsushita¹, Tadahiro Kobayashi², Yasuhito Hamaguchi², Minoru Hasegawa³, Manabu Fujimoto⁴ and Kazuhiko Takehara¹, ¹Kanazawa University, Department of Dermatology, Kanazawa, Japan, ²Department of Dermatology, Kanazawa University, Kanazawa, Japan, ³University of Fukui, Department of Dermatology, Fukui, Japan, ⁴University of Tsukuba, Faculty of Medicine, Department of Dermatology, Tsukuba, Japan
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by skin and lung fibrosis. Over 90% of patients with SSc are positive for autoantibodies. In…
Abstract Number: 2099 • 2018 ACR/ARHP Annual Meeting
Bruton’s Tyrosine Kinase (BTK) Inhibition Modulates Multiple Cell Types Instrumental in the Pathogenesis of Lupus Nephritis
Samantha Chalmers¹, Sayra Garcia¹, Elliott Klein², Jay S. Fine², Gerald Nabozny³, Meera Ramanujam² and Chaim Putterman⁴, ¹Albert Einstein College of Medicine, Bronx, NY, ²Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ³[email protected], Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁴Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE) that adds substantial morbidity and mortality. Passive transfer of pre-formed nephritogenic antibodies…
Abstract Number: 13 • 2018 ACR/ARHP Annual Meeting
Shared Genetic Origins Among Anti-Proteinase 3 and Anti-Glomerular Basement Membrane Double-Positive Human Autoantibodies
Jeffrey R. Ord¹, Amy G. Clark¹ and Mary H. Foster², ¹Duke University Medical Center, Durham, NC, ²Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Patients with ANCA vasculitis and anti-glomerular basement membrane (GBM) nephritis (Goodpasture’s Disease) develop pathogenic autoantibodies (autoAb) that destroy the microvasculature in lungs and kidneys.…
Abstract Number: 534 • 2018 ACR/ARHP Annual Meeting
Increased Insulin Resistance and Impaired Beta-Cell Function in Patients with Rheumatoid Arthritis: The Role of Glucocorticoid Therapy?
Gorica Ristic¹, Vesna Subota², Dejana Stanisavljevic³, Branislava Glisic¹, Milan Petronijevic¹ and Dusan Stefanovic¹, ¹Department of Rheumatology and Clinical Immunology, Military Medical Academy, Belgrade, Serbia, ²Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia, ³Institute of Medical Statistics, Belgrade University School of Medicine, Belgrade, Serbia
Background/Purpose: Increased insulin resistance and impaired β-cell function have been demonstrated in rheumatoid arthritis (RA). The aim of the study was to analyze the association…
Abstract Number: 2288 • 2018 ACR/ARHP Annual Meeting
Preexisting Anti-Acetylcholine Receptor Autoantibodies and B Cell Lymphopenia Are Associated with the Development of Myositis in Thymoma Patients Treated with Avelumab, an Immune Checkpoint Inhibitor Targeting Programmed Death-Ligand 1
Andrew Mammen¹, Arun Rajan², Katherine Pak¹, Tanya Lehky³, Livia Casciola-Rosen⁴, Renee Donahue², Lauren Lepone², Anastasia Zekeridou⁵, Sean Pittock⁵, Raffit Hassan², Jeffrey Schlom² and James Gulley², ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²NCI, NIH, Bethesda, MD, ³NINDS, NIH, Bethesda, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Neurology, Mayo Clinic, Rochester, MN
Background/Purpose: Immune checkpoint inhibitors (ICIs) enhance the immune response against tumors but may also trigger immune-related adverse events (IRAEs). Myositis following receipt of ICIs is…
Abstract Number: 14 • 2018 ACR/ARHP Annual Meeting
Individual RA-Derived Monoclonal Anti-Citrullinated Protein Autoantibodies (ACPA) Have Extensive Citrulline Multi-Reactivity Demonstrated By a Large-Scale Protein Array Platform
Peter Sahlström¹, Johanna Steen¹, Madeleine Jenning², Philip J. Titcombe^1,3, Ute Nonhoff^4,5, Ragnhild Stålesen⁶, Bianka Marklein², Daniel L. Mueller³, Zoltan Konthur⁴, Karin Lundberg⁷, Anca I. Catrina⁶, Lars Klareskog¹, Vivianne Malmström¹, Karl Skriner² and Caroline Grönwall⁸, ¹Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Dept. of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ³The Center for Immunology, Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, ⁴Engine GmbH, Hennigsdorf, Germany, ⁵Max Planck Institute of Colloids and Interfaces, Potsdam, Germany, ⁶Rheumatology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁷Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁸Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The presence of serum IgG anti-citrullinated protein autoantibodies (ACPA) in rheumatoid arthritis (RA), is associated with more aggressive disease progression. Although ACPA have been…
Abstract Number: 595 • 2018 ACR/ARHP Annual Meeting
Predictive VALUE of CD19 SERUM Levels for LONG TERM Therapeutic Response and Utility As Biomarker for Optimization, in Rheumatoid Arthritis Patients Treated with Rituximab
Sheila Melchor¹, Esther Rodriguez-Almaraz², Jose L. Pablos³ and Patricia Carreira⁴, ¹Rheumatology, Rheumatology Department, Hospital Universitario 12 de Octubre, Spain., Madrid, Spain, ²Hospital Universitario 12 de Octubre, Madrid, Spain, ³Servicio de Reumatología, Rheumatology Department, Hospital 12 de Octubre, Spain, Madrid, Spain, ⁴Rheumatology Department. Hospital Universitario 12 de Octubre, Madrid, Spain
Background/Purpose: Rituximab (RTX) is directed against CD20 antigens in B lymphocytes (BL), producing selective depletion of BL, not affecting mature plasmatic cells, without immediate effect…
Abstract Number: 2671 • 2018 ACR/ARHP Annual Meeting
Development and First-in-Human Characterization of an ICOSL and BAFF Bispecific Inhibitor AMG 570 for SLE Treatment
Laurence E Cheng¹, Hailing Hsu², Martin Kankam³, Nicholas Siebers⁴, Randall Stoltz⁵, Lubna Abuqayyas², Bella Ertik⁶, Barbara Sullivan², Lei Zhou² and Jane R Parnes², ¹Amgen Inc., South San Francisco, CA, ²Amgen Inc., Thousand Oaks, CA, ³Vince and Associates Clinical Research, Inc.,, Overland Park, KS, ⁴Covance, Madison, WI, ⁵Covance, Evansville, IN, ⁶Amgen Inc, Boston, MA
Background/Purpose: Autoimmune diseases, including systemic lupus erythematosus (SLE), are associated with dysregulated T cell and B cell responses. AMG 570 is a bispecific molecule targeting…
Abstract Number: 17 • 2018 ACR/ARHP Annual Meeting
Kappa-Deleting Recombination Excision Circles (KREC) in B Cells and Serum B Cell Activating Factor (BAFF): Possible Aids in Predicting Juvenile Dermatomyositis Response to Rituximab
Amer khojah^1,2, Victoria Hans³, Wilfredo Marin⁴, Gabrielle A. Morgan⁴ and Lauren M. Pachman^5,6,7, ¹Division of Pediatric Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Division of Pediatric Allergy Immunology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Cure JM Program of Excellence in Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁵Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁶Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Rheumatology/Immunology, Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, IL
Background/Purpose: Rituximab is used for the treatment of juvenile dermatomyositis (JDM) with variable success. Some of this variability is presumed to be related to the…
Abstract Number: 714 • 2018 ACR/ARHP Annual Meeting
A Predictive Clinical-Immunological Index for Infections Unveils Novel Innate and Adaptive Immunity Abnormalities As Key Risk Factors for Infections in a Cohort of Patients with Systemic Lupus Erythematosus
Diana Gómez-Martín^1,2, Jiram Torres-Ruíz³, Nancy R Mejía-Domínguez⁴, Guillermo Juárez-Vega⁵, Javier Merayo-Chalico³, Ana Barrera-Vargas³ and Jorge Alcocer-Varela¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico, ⁴Bioinformatics, Biostatistics and Computational Biology Unit, Red de Apoyo a la Investigación. Coordinación de la Investigación Científica, Universidad Nacional Autónoma de México, Mexico, Mexico, ⁵Flow Cytometry Unit, Red de Apoyo a la Investigación. Coordinación de la Investigación Científica, Universidad Nacional Autónoma de México, Mexico, Mexico
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have multiple innate and adaptive immune response abnormalities. It is unknown whether they play a key role in…
Abstract Number: 2743 • 2018 ACR/ARHP Annual Meeting
Favorable Efficacy of Rituximab in ANCA-Associated Vasculitis Patients with Excessive B Cell Differentiation
Yusuke Miyazaki¹, Shingo Nakayamada¹, Satoshi Kubo¹, Kazuhisa Nakano¹, Shigeru Iwata², Shunsuke Fukuyo³, Akio Kawabe⁴ and Yoshiya Tanaka⁵, ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health, Japan, Fukuoka, Japan, ⁴University of Occupational and Environmental Health, Japan, Kitakyusyu, Japan, ⁵University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: B cell depletion by rituximab (RTX)is effective treatment for ANCA-associated vasculitis (AAV). However, the phenotype of peripheral B cells and the selection criteria for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].